Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 3/20 | 0.32 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23386192 | 0.81 | DRD2 (0.31) | DRD2DRD3AVPR1A | |
| SCHEMBL11418047 | 0.76 | CYP11B2 (0.38) | DRD2DRD3AVPR1A | |
| SCHEMBL23811488 | 0.73 | DRD2 (0.33) | DRD2DRD3AVPR1A | |
| SCHEMBL23509314 | 0.71 | GRIN2D (0.41) | AVPR1A | |
| SCHEMBL26428055 | 0.70 | PDK2 (0.35) | DRD2DRD3NAMPTAVPR1A | |
| SCHEMBL24677864 | 0.70 | DRD2 (0.37) | DRD2DRD3AVPR1A | |
| SCHEMBL24112694 | 0.69 | NAMPT (0.32) | DRD2DRD3NAMPT | |
| SCHEMBL22958207 | 0.68 | TSHR (0.36) | DRD2DRD3AVPR1A | |
| SCHEMBL21142424 | 0.68 | NPC1 (0.37) | DRD2DRD3NAMPT | |
| SCHEMBL25070433 | 0.68 | CHRNB2 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127271-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC SHP2 INHIBITOR COMPOUND, PREPARATION METHOD, AND USE | SHANGHAI RINGENE BIOPHARMA CO., LTD. (CN) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127271-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC SHP2 INHIBITOR COMPOUND, PREPARATION METHOD, AND USE | PTPN1, PTPN7, PTPN9 | DRD2 4750/4885DRD3 4789/4885NAMPT 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.